Horizons Marijuana ETF (TSX:HMMJ): Best Way to Bet on a Cannabis Rebound?

Horizons Marijuana Life Sciences ETF (TSX:HMMJ) stock could be the ultimate proxy for a rebound in the legal pot sector.

| More on:
edit Jars of marijuana

Image source: Getty Images

Cannabis stocks have had a rough year. Investors in the sector have collectively lost billions of dollars, while the stocks are trading at their lowest valuations since 2017. Market sentiment has turned decisively pessimistic, which makes the sector fertile ground for contrarian investors. 

Value-oriented investors probably understand that the top players in this sector are gearing up for a better year ahead. The roll-out of Cannabis 2.0 products, the relaxation of licensing rules in Ontario, along with ongoing involvement of major established corporations like Constellation Brands and Altria, all indicate that the market could bounce back in 2020. 

However, I still believe it is way too risky to bet on any individual stock in this sector. Even the largest marijuana producers could face cash flow issues or debt-repayment problems that could drag them down, while the rest of the sector recovers and snatches away their market share. It’s simply too difficult to pick stocks with conviction here. 

Instead, I believe investors should take a pragmatic approach and invest in the broader market through an exchange-traded fund (ETF) like Horizons Marijuana Life Sciences ETF (TSX:HMMJ). Here are three reasons why betting on this ETF is better than trying to pick winners or losers in the Canadian marijuana sector in 2020

Diversification

The most obvious benefit of investing in an ETF rather than stock picking is the way risk is mitigated through diversification. HMMJ owns a stake in the top 55 publicly listed marijuana stocks. The exposure to these holdings is weighted by market capitalization, which means the industry leaders account for the biggest portion of the overall portfolio. 

This level of diversification also means that the downside is limited when any one company fails. CannTrust, for example, was a larger part of the portfolio at the start of 2019 but now accounts for a smaller fraction since its stock price plummeted. Meanwhile, the larger stocks that performed relatively better offset the losers. 

This makes the HMMJ ETF a barometre for the entire industry. In other words, it’s a bet on consumer demand for marijuana rather than the success of any individual company. 

Steady income

Another reason HMMJ is an ideal bet is the fact that it offers a dividend to shareholders. Admittedly, it’s surprising that a portfolio of money-losing companies pays a dividend, yet that seems to be the case. In fact, the trailing dividend yield is impressively high at 12.4%. 

Here’s the secret: HMMJ isn’t paying a dividend from the profits of its underlying stocks. Instead, the ETF management company generates income by lending the stocks to short-sellers and daily traders. The interest earned on this short-selling activity is passed onto investors in the form of dividends. 

In other words, HMMJ benefits from the market collapse as well.  

Fair value

Like any other ETF, HMMJ’s market price is usually misaligned with the net value of its underlying holdings. Generally, the ETF has traded at a discount to net asset value (NAV). However, at the moment it is trading at par with NAV. 

In other words, the ETF is fairly valued. However, you could wait for another discount to emerge to add exposure if you’re feeling adventurous. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends CannTrust Holdings, CannTrust Holdings Inc, and Constellation Brands. Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Is Cronos Group (TSX:CRON) a Buy After its 1st-Quarter Performance?

Cronos Group remains a high-risk, high-reward stock, despite its solid first-quarter performance.

Read more »

Cannabis smoke
Cannabis Stocks

Aurora Cannabis Stock Hits 52-Week Low: What Investors Should Know

Aurora Cannabis stock continues to fall, hitting a yearly bottom last week. So what should investors do now?

Read more »

edit Jars of marijuana
Cannabis Stocks

Here’s Why Curaleaf Is a Better Cannabis Stock Compared to Sundial!

Cannabis giant Curaleaf ended 2021 with $1.2 billion in sales, making it one of the largest marijuana companies in the…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

2 Cannabis Stocks Better Than Sundial Growers

Here's why Green Thumb Industries and Cresco Labs are much better long-term bets compared to Sundial Growers.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Hexo Stock Jumps 10% on Definitive Tilray Deal

Hexo (TSX:HEXO)(NASDAQ:HEXO) stock jumped 10% on Monday, as its deal with Tilray (TSX:TLRY)(NASDAQ:TLRY) stock became official.

Read more »

edit Jars of marijuana
Cannabis Stocks

Down 97% From Record Highs, Is Sundial Stock a Buy Right Now?

Despite the 97% decline in Sundial stock from its record high, it remains a risky bet for long-term investors due…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Tilray Stock Rallied After its Q3 Results

Here's why Tilray (TSX:TLRY) stock jumped sharply after announcing its Q3 results.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Tuesday, March 29

TSX investors may want to keep an eye on the latest consumer confidence and job openings data from the U.S.…

Read more »